At a glance
ClinicalIndex Comparison RecordN/ACompleted· 88 enrolled
Drug / intervention
beta-tricalcium phosphate alone +3 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Controlled, Multicenter Dose Verification Clinical Trial to Evaluate the Safety and Effectiveness of GUIDOR® Growth Factor Enhanced Bone Graft Substitute for the Treatment of Periodontal Defects 6-months Post-Surgery
In Brief
A clinical study evaluating beta-tricalcium phosphate alone, GFeBGS 0.1%, and 2 other interventions for Alveolar Bone Loss and Periodontal Diseases. Completed, enrolled 88 participants across 6 sites.
Detailed Summary
GUIDOR Growth Factor Enchanted Bone Graft Substitute (GFeBGS) when used in periodontal surgery will shown greater gum and bone regeneration when compare to bone graft substitute alone. Also, to find the optimal dose.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlveolar Bone Loss, Periodontal Diseases
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2012
First PostedNov 2012
Primary CompletionAug 2014
TodayJul 2026
First PostedNov 20, 2012
Enrollment StartOct 1, 2012
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 13.6 years ago
Interventions
beta-tricalcium phosphate alonedevice
GFeBGS 0.1%device
GFeBGS 0.3%device
GFeBGS 0.4%device